Okay, here’s a breakdown of the references provided, formatted for clarity:
1. Blauvelt A, et al. Rocatinlimab demonstrates rapid and sustained improvement in itch and skin lesions in patients with moderate-to-severe atopic dermatitis: results from the ROCKET-IGNITE Phase 2 trial. Journal of the American Academy of Dermatology. 2024;80(2):418-426. https://www.jaad.org/article/S0190-9622(23)02394-1/fulltext02394-1/fulltext)
2. Amgen. Positive Phase 3 Results for Amgen’s Rocatinlimab in Adults with Moderate-to-Severe Atopic Dermatitis. News Release. November 21, 2023. Accessed January 21, 2026. https://www.eurekalert.org/news-releases/1107503
3. A Study Evaluating Rocatinlimab in Moderate-to-severe atopic Dermatitis (ROCKET-IGNITE) (ROCKET-ignite). Updated november 24, 2025. Accessed January 21, 2026. https://clinicaltrials.gov/study/NCT05398445
4. A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) (ROCKET-Horizon). updated April 3, 2025. Accessed January 21, 2026. https://clinicaltrials.gov/study/NCT05651711
Key Observations:
* Rocatinlimab: All references relate to a drug called Rocatinlimab (also known as AMG 451) being investigated for the treatment of moderate-to-severe atopic dermatitis (eczema).
* study Types: The references include a published journal article (JAAD), a press release from the pharmaceutical company Amgen, and records for clinical trials registered on ClinicalTrials.gov.
* Clinical Trial Names: Two specific clinical trials are mentioned: ROCKET-IGNITE and ROCKET-Horizon.
* Dates: The dates provided are a mix of publication/update dates and access dates. The access dates are in the future (January 21, 2026), which is a bit unusual, suggesting this list was prepared in advance.
Let me know if you’d like me to do anything else with this details, such as summarize the findings of the studies (if available from the links) or analyze the source types.
